Your browser doesn't support javascript.
loading
Autoantibodies to the N-Methyl-D-Aspartate Receptor in Adolescents With Early Onset Psychosis and Healthy Controls.
Engen, Kristine; Wortinger, Laura Anne; Jørgensen, Kjetil Nordbø; Lundberg, Mathias; Bohman, Hannes; Smelror, Runar Elle; Myhre, Anne Margrethe; Jacobson, Leslie; Vincent, Angela; Agartz, Ingrid.
Afiliação
  • Engen K; Department of Psychiatric Research, Diakonhjemmet Hospital, Oslo, Norway.
  • Wortinger LA; NORMENT, Institute of Clinical Medicine, University of Oslo, Oslo, Norway.
  • Jørgensen KN; Department of Psychiatric Research, Diakonhjemmet Hospital, Oslo, Norway.
  • Lundberg M; NORMENT, Institute of Clinical Medicine, University of Oslo, Oslo, Norway.
  • Bohman H; Department of Psychiatric Research, Diakonhjemmet Hospital, Oslo, Norway.
  • Smelror RE; NORMENT, Institute of Clinical Medicine, University of Oslo, Oslo, Norway.
  • Myhre AM; Department of Neuroscience, Child and Adolescent Psychiatry Unit, Uppsala University, Uppsala, Sweden.
  • Jacobson L; Department of Clinical Science and Education, Södersjukhuset, Karolinska Institutet, Stockholm, Sweden.
  • Vincent A; Department of Neuroscience, Child and Adolescent Psychiatry Unit, Uppsala University, Uppsala, Sweden.
  • Agartz I; Department of Clinical Science and Education, Södersjukhuset, Karolinska Institutet, Stockholm, Sweden.
Front Psychiatry ; 11: 666, 2020.
Article em En | MEDLINE | ID: mdl-32765314
ABSTRACT

BACKGROUND:

Autoantibodies to the N-methyl-D-aspartate receptor (NMDAR-Abs) in autoimmune encephalitis have been associated with prominent psychiatric symptoms. The aims of the present study are to identify the prevalence of NMDAR-Abs in adolescents with early onset psychosis disorders (EOP) and healthy controls (HC) and examine its clinical significance.

METHOD:

Plasma samples were acquired from 46 adolescent EOP patients and 69 age- and sex matched HC, and assessed for the presence of immunoglobulin G NMDAR-Abs. All participants underwent psychiatric evaluation, neurological examination and head magnetic resonance imaging.

RESULTS:

NMDAR-Abs were detected in three of 46 (6.5%) EOP patients and in two of 69 (2.9%) HC. One NMDAR-Abs EOP patient presented with unusual psychopathology and minor T1 weighted lesions of vasculopathological origin located bi-frontally and in the basal ganglia, and had a recent diagnosis of a separate autoimmune disease. One NMDAR-Ab HC displayed a T2 weighted FLAIR hyperintensity lesion in the left frontal lobe. The remaining three NMDAR-Ab participants were two EOP patients without neurological or radiological findings, and one HC without any clinical findings.

CONCLUSIONS:

We report that a small number of EOP patients and HC have NMDAR-Abs with a similar frequency in both groups. The presence of the antibodies was not associated with any distinctive clinical or radiological features. Detection of the antibodies had no diagnostic implication, and a positive NMDAR antibody test must be carefully interpreted and reviewed within the individual clinical context.
Palavras-chave

Texto completo: 1 Base de dados: MEDLINE Idioma: En Ano de publicação: 2020 Tipo de documento: Article

Texto completo: 1 Base de dados: MEDLINE Idioma: En Ano de publicação: 2020 Tipo de documento: Article